JavaScript NENÍ povolen !

* Zobrazit nápovědu

MeSH: cyklické N-oxidy-terapeutické užití

10 záznamů v Medvik Filtry

Článek online

Nová přímá perorální antikoagulancia - nové molekuly ve výzkumu
[New direct oral anticoagulances - new molecules in research]

Zatloukalová, Anna
Autor Autorita Lékařská fakulta, Centrum epidemiologického výzkumu, Ostravská univerzita Univerzita Palackého Olomouc, Fakulta zdravotnických věd, Univerzita Palackého Olomouc Ústav zdravotnického managementu, Univerzita Palackého Olomouc

Klinická farmakologie a farmacie. 2020 ; 34 (2) : 84-88.

ISSN 1212-7973
Medvik
Zdroj

V současné době nová přímá perorální antikoagulancia (DOAC) postupně nahrazují dosavadní historicky nejčastěji užívaný warfarin. Jedná se o dvě skupiny léčiv přímo inhibující faktor Xa (Xarelto, Eliquis, Lixiana) a trombin (Pradaxa). Nabízí mnohá pozitiva, která ocení i samotní pacienti. Jedná se zejména o odpadnutí nutnosti pravidelné monitorace, minimum lékových a potravinových interakcí či příznivý bezpečnostní profil. Nicméně jako jednu z nevýhod lze vnímat nepřítomnost antidota při předávkování. Své specifické antidotum - Idarucizumab - má v současné době pouze Pradaxa. Ostatní jsou ve vývoji, stejně tak jako nové molekuly samotných antikoagulancií.

Currently, new direct oral anticoagulants (DOAC) are gradually replacing the historically most frequently used warfarin. These are two classes of drugs directly inhibiting factor Xa (Xarelto, Eliquis, Lixiana) and thrombin (Pradaxa). It offers many positives that patients themselves will appreciate. These include, in particular, no need for regular monitoring, minimal drug and food interactions, or afavorable safety profile. However, one of the drawbacks is the absence of antidotes for overdose. Only Pradaxa currently has its specific antidote - Idarucizumab. Others are in development as well as new molecules of anticoagulants themselves.

Článek online

Nová přímá perorální antikoagulancia -nové molekuly ve výzkumu
[New direct oral anticoagulances - new molecules in research]

Zatloukalová, Anna
Autor Autorita Lékařská fakulta, Centrum epidemiologického výzkumu, Ostravská univerzita Univerzita Palackého Olomouc, Fakulta zdravotnických věd, Univerzita Palackého Olomouc Ústav zdravotnického managementu, Univerzita Palackého Olomouc

Praktické lékárenství. 2020 ; 16 (4) : 3-12.

ISSN 1801-2434
Medvik
Zdroj

Článek

Tempol alleviates chronic intermittent hypoxia-induced pancreatic injury through repressing inflammation and apoptosis

Physiological research. 2019 ; 68 (3) : 445-455. [pub] 20190630

Physiol. Res. (Print)
ISSN 1802-9973
Medvik
Zdroj

Obstructive sleep apnea (OSA) has been demonstrated to be implicated in disorder of insulin secretion and diabetes mellitus. In this study, we aimed to evaluate the protective role of tempol, a powerful antioxidant, in chronic intermittent hypoxia (IH)-induced pancreatic injury. The rat model of OSA was established by IH exposure. The pathological changes, increased blood-glucose level, and raised proinsulin/insulin ratio in pancreatic tissues of rats received IH were effectively relieved by tempol delivery. In addition, the enhanced levels of pro-inflammatory cytokines, TNF-alpha, IL-1beta, IL-6, and inflammatory mediators, PGE2, cyclooxygenase-2 (COX-2), NO, and inducible nitric oxide synthase (iNOS) in pancreatic tissue were suppressed by tempol. Moreover, tempol inhibited IH-induced apoptosis in pancreatic tissue as evidenced by upregulated Bcl-2 level, and downregulated Bax and cleaved caspase-3 levels. Finally, the abnormal activation of mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling pathways induced by IH was restrained by tempol administration. In summary, our study demonstrates that tempol relieves IH-induced pancreatic injury by inhibiting inflammatory response and apoptosis, which provides theoretical basis for tempol as an effective treatment for OSA-induced pancreatic injury.

MeSH
antioxidancia farmakologie terapeutické užití MeSH
apoptóza účinky léků fyziologie MeSH
cyklické N-oxidy farmakologie terapeutické užití MeSH
hypoxie farmakoterapie metabolismus patologie MeSH
krysa rodu rattus MeSH
mediátory zánětu antagonisté a inhibitory metabolismus MeSH
obstrukční spánková apnoe farmakoterapie metabolismus patologie MeSH
pankreas účinky léků metabolismus patologie MeSH
potkani Wistar MeSH
spinové značení MeSH
zánět farmakoterapie metabolismus patologie MeSH
zvířata MeSH
Check Tag
krysa rodu rattus MeSH
zvířata MeSH
Publikační typ
časopisecké články MeSH

Článek

Studie Aminexil clinical 5: Až o 20 % více vlasů za 8 týdnů

Referátový výběr z dermatovenerologie (2002, Print). 2017 ; 59 (5) : 38-40.

ISSN 1213-9106
Medvik
Zdroj

Klíčová slova
šampon Aminexil,
MeSH
alopecie * farmakoterapie MeSH
cyklické N-oxidy terapeutické užití MeSH
dospělí MeSH
kosmetické přípravky terapeutické užití MeSH
lékové roztoky terapeutické užití MeSH
lidé středního věku MeSH
lidé MeSH
pyrimidiny terapeutické užití MeSH
výsledek terapie MeSH
Check Tag
dospělí MeSH
lidé středního věku MeSH
lidé MeSH
mužské pohlaví MeSH
ženské pohlaví MeSH
Publikační typ
klinické zkoušky MeSH

Článek

ROS scavenger decreases basal perfusion pressure, vasoconstriction and NO synthase activity in pulmonary circulation during pulmonary microembolism

Physiological research. 2015 ; 64 (5) : 683-688. [pub] 2015Mar24

Physiol. Res. (Print)
ISSN 1802-9973
Medvik
Zdroj

Two mechanisms contribute in the development of pulmonary hypertension in pulmonary embolism (PE) - obstruction of pulmonary blood vessels and vasoconstriction. We hypothesize that hypoxia, increased shear stress and/or activation of gathered leukocytes in the PE may cause a release of reactive oxygen species (ROS). Therefore our aim was to determine the influence of the ROS scavenger Tempol on pulmonary hypertension and to describe NO synthase activity and production of NO oxidative products (NOx) after PE. In general anesthesia sephadex microspheres suspended in PSS were applied in right jugular vein as the pulmonary microembolism. Than we measured in isolated salt solution-perfused lungs the changes in perfusion pressure, activity of NO synthase and NOx plasma concentration in 7 groups of rats: C: control group (n=5), CN: C + sodium nitroprusside (SN) (n=5), EN: PE + SN (n=5), ETN: Tempol + PE + SN (n=5), CL: C + L-NAME (n=5), EL: PE + L-NAME (n=5), ETL: Tempol + PE + L-NAME (n=5). Tempol was applied intraperitoneally before PE. Animals that received Tempol (groups TN, TL) had significantly lower basal perfusion pressure than those which did not receive Tempol (EN, EL). Overall we measured a higher decrease of perfusion pressure than in the control group (C) after application of SN. Administration of L-NAME after PE (EL) increased the pressure more than in the control group (NL). NOx concentration was higher after PE. We found that preventive administration of Tempol decreases the increase in perfusion pressure after PE. PE increased NO release and concentration of NOx.

Článek

Upper airway dilator muscle weakness following intermittent and sustained hypoxia in the rat: effects of a superoxide scavenger

Physiological research. 2013 ; 62 (2) : 187-196.

Physiol. Res. (Print)
ISSN 1802-9973
Medvik
Zdroj

Obstructive sleep apnoea syndrome (OSAS) is a common disorder associated with upper airway muscle dysfunction. Agents that improve respiratory muscle performance may have considerable therapeutic value. We examined the effects of acute exposure to sustained and intermittent hypoxia on rat pharyngeal dilator muscle function. Additionally, we sought to test the efficacy of antioxidant treatment in ameliorating or preventing hypoxia-related muscle dysfunction. Isometric contractile and endurance properties of isolated rat sternohyoid muscle bundles were examined at 35 °C in vitro. Muscle bundles were exposed to one of four gas treatments: hyperoxia (control), sustained hypoxia (SH), intermittent hypoxia (IH) or hypoxia/re-oxygenation (HR), in the absence or presence of the superoxide scavenger--Tempol (10 mM). Stress-frequency relationship was determined in response to electrical stimulation (10-100 Hz in increments of 10-20 Hz, train duration: 300 ms). Muscle performance was also assessed during repetitive muscle stimulation (40 Hz, 300 ms every 2 s for 2.5 min). Compared to control, IH and HR treatments significantly decreased sternohyoid muscle force. The negative inotropic effect of the two gas protocols was similar, but both were of lesser magnitude than the effects of SH. SH, but not IH and HR, increased muscle fatigue. Tempol significantly increased sensitivity to stimulation in all muscle preparations and caused a leftward shift in the stress-frequency relationship of IH and SH treated muscles. Tempol did not ameliorate sternohyoid muscle fatigue during SH. We conclude that Tempol increases upper airway muscle sensitivity to stimulation but only modestly ameliorates respiratory muscle weakness during intermittent and sustained hypoxic conditions in vitro. Respiratory muscle fatigue during sustained hypoxia appears unrelated to oxidative stress.